Regeneron $REGN Shares Down 50% from Peak Despite Robust Q1...
Key Takeaways Regeneron maintains a strong R&D-driven strategy, leading to continued success with core products including Dupixent and Eylea. Q1 2025 results highlight revenue of $3.0 billion, with Dupixent sales...